Myelomonocytic cells are sufficient for therapeutic cell fusion in liver

Holger Willenbring, Alexis S. Bailey, Mark Foster, Yassmine Akkari, Craig Dorrell, Susan Olson, Milton Finegold, William Fleming, Markus Grompe

Research output: Contribution to journalArticle

337 Citations (Scopus)

Abstract

Liver repopulation with bone marrow-derived hepatocytes (BMHs) can cure the genetic liver disease fumarylacetoacetate hydrolase (Fah) deficiency. BMHs emerge from fusion between donor bone marrow-derived cells and host hepatocytes. To use such in vivo cell fusion efficiently for therapy requires knowing the nature of the hematopoietic cells that fuse with hepatocytes. Here we show that the transplantation into Fah-/- mice of hematopoietic stem cells (HSCs) from lymphocyte-deficient Rag1-/- mice, lineage-committed granulocyte-macrophage progenitors (GMPs) or bone marrow-derived macrophages (BMMs) results in the robust production of BMHs. These results provide direct evidence that committed myelomonocytic cells such as macrophages can produce functional epithelial cells by in vivo fusion. Because stable bone marrow engraftment or HSCs are not required for this process, macrophages or their highly proliferative progenitors provide potential for targeted and well-tolerated cell therapy aimed at organ regeneration.

Original languageEnglish (US)
Pages (from-to)744-748
Number of pages5
JournalNature Medicine
Volume10
Issue number7
DOIs
StatePublished - Jul 2004

Fingerprint

Cell Fusion
Liver
Hepatocytes
Bone
Fusion reactions
Macrophages
Bone Marrow
Hematopoietic Stem Cells
Stem cells
Therapeutics
Granulocyte-Macrophage Progenitor Cells
Inborn Genetic Diseases
Cell- and Tissue-Based Therapy
Lymphocytes
Bone Marrow Cells
Electric fuses
Liver Diseases
Regeneration
Transplantation
Epithelial Cells

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Willenbring, H., Bailey, A. S., Foster, M., Akkari, Y., Dorrell, C., Olson, S., ... Grompe, M. (2004). Myelomonocytic cells are sufficient for therapeutic cell fusion in liver. Nature Medicine, 10(7), 744-748. https://doi.org/10.1038/nm1062

Myelomonocytic cells are sufficient for therapeutic cell fusion in liver. / Willenbring, Holger; Bailey, Alexis S.; Foster, Mark; Akkari, Yassmine; Dorrell, Craig; Olson, Susan; Finegold, Milton; Fleming, William; Grompe, Markus.

In: Nature Medicine, Vol. 10, No. 7, 07.2004, p. 744-748.

Research output: Contribution to journalArticle

Willenbring, H, Bailey, AS, Foster, M, Akkari, Y, Dorrell, C, Olson, S, Finegold, M, Fleming, W & Grompe, M 2004, 'Myelomonocytic cells are sufficient for therapeutic cell fusion in liver', Nature Medicine, vol. 10, no. 7, pp. 744-748. https://doi.org/10.1038/nm1062
Willenbring H, Bailey AS, Foster M, Akkari Y, Dorrell C, Olson S et al. Myelomonocytic cells are sufficient for therapeutic cell fusion in liver. Nature Medicine. 2004 Jul;10(7):744-748. https://doi.org/10.1038/nm1062
Willenbring, Holger ; Bailey, Alexis S. ; Foster, Mark ; Akkari, Yassmine ; Dorrell, Craig ; Olson, Susan ; Finegold, Milton ; Fleming, William ; Grompe, Markus. / Myelomonocytic cells are sufficient for therapeutic cell fusion in liver. In: Nature Medicine. 2004 ; Vol. 10, No. 7. pp. 744-748.
@article{b25162327cbd49a9a082b9d206e14901,
title = "Myelomonocytic cells are sufficient for therapeutic cell fusion in liver",
abstract = "Liver repopulation with bone marrow-derived hepatocytes (BMHs) can cure the genetic liver disease fumarylacetoacetate hydrolase (Fah) deficiency. BMHs emerge from fusion between donor bone marrow-derived cells and host hepatocytes. To use such in vivo cell fusion efficiently for therapy requires knowing the nature of the hematopoietic cells that fuse with hepatocytes. Here we show that the transplantation into Fah-/- mice of hematopoietic stem cells (HSCs) from lymphocyte-deficient Rag1-/- mice, lineage-committed granulocyte-macrophage progenitors (GMPs) or bone marrow-derived macrophages (BMMs) results in the robust production of BMHs. These results provide direct evidence that committed myelomonocytic cells such as macrophages can produce functional epithelial cells by in vivo fusion. Because stable bone marrow engraftment or HSCs are not required for this process, macrophages or their highly proliferative progenitors provide potential for targeted and well-tolerated cell therapy aimed at organ regeneration.",
author = "Holger Willenbring and Bailey, {Alexis S.} and Mark Foster and Yassmine Akkari and Craig Dorrell and Susan Olson and Milton Finegold and William Fleming and Markus Grompe",
year = "2004",
month = "7",
doi = "10.1038/nm1062",
language = "English (US)",
volume = "10",
pages = "744--748",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Myelomonocytic cells are sufficient for therapeutic cell fusion in liver

AU - Willenbring, Holger

AU - Bailey, Alexis S.

AU - Foster, Mark

AU - Akkari, Yassmine

AU - Dorrell, Craig

AU - Olson, Susan

AU - Finegold, Milton

AU - Fleming, William

AU - Grompe, Markus

PY - 2004/7

Y1 - 2004/7

N2 - Liver repopulation with bone marrow-derived hepatocytes (BMHs) can cure the genetic liver disease fumarylacetoacetate hydrolase (Fah) deficiency. BMHs emerge from fusion between donor bone marrow-derived cells and host hepatocytes. To use such in vivo cell fusion efficiently for therapy requires knowing the nature of the hematopoietic cells that fuse with hepatocytes. Here we show that the transplantation into Fah-/- mice of hematopoietic stem cells (HSCs) from lymphocyte-deficient Rag1-/- mice, lineage-committed granulocyte-macrophage progenitors (GMPs) or bone marrow-derived macrophages (BMMs) results in the robust production of BMHs. These results provide direct evidence that committed myelomonocytic cells such as macrophages can produce functional epithelial cells by in vivo fusion. Because stable bone marrow engraftment or HSCs are not required for this process, macrophages or their highly proliferative progenitors provide potential for targeted and well-tolerated cell therapy aimed at organ regeneration.

AB - Liver repopulation with bone marrow-derived hepatocytes (BMHs) can cure the genetic liver disease fumarylacetoacetate hydrolase (Fah) deficiency. BMHs emerge from fusion between donor bone marrow-derived cells and host hepatocytes. To use such in vivo cell fusion efficiently for therapy requires knowing the nature of the hematopoietic cells that fuse with hepatocytes. Here we show that the transplantation into Fah-/- mice of hematopoietic stem cells (HSCs) from lymphocyte-deficient Rag1-/- mice, lineage-committed granulocyte-macrophage progenitors (GMPs) or bone marrow-derived macrophages (BMMs) results in the robust production of BMHs. These results provide direct evidence that committed myelomonocytic cells such as macrophages can produce functional epithelial cells by in vivo fusion. Because stable bone marrow engraftment or HSCs are not required for this process, macrophages or their highly proliferative progenitors provide potential for targeted and well-tolerated cell therapy aimed at organ regeneration.

UR - http://www.scopus.com/inward/record.url?scp=3142734226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142734226&partnerID=8YFLogxK

U2 - 10.1038/nm1062

DO - 10.1038/nm1062

M3 - Article

VL - 10

SP - 744

EP - 748

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 7

ER -